For those choosing to go vegan, the doctor said, it’s important to “increase soluble fiber, focus on whole foods, which are ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

Increased levels of Low-density lipoprotein (LDL) can put th heart health at risk. Elevated levels of cholesterol can be due to sedentary lifestyle, no physical activity, consuming unhealthy diet, ...

Zerlasiran was found to be well tolerated and no significant safety concerns were observed. Credit: Good dreams - Studio via ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...

Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...

Lp (a) is a genetically driven variant of low-density lipoprotein (LDL) cholesterol, that is known to be an independent risk ...

Low-density lipoprotein (LDL) cholesterol: We call LDL "bad" cholesterol. Below 100 milligrams per deciliter (mg/dl) is ...

The prevalence of high total cholesterol was 11.3 percent among U.S. adults in August 2021 to August 2023, according to a ...

Eli Lilly (LLY) and Company announced “positive” Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a), or Lp(a), a genetically ...

"AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein (a)" was originally created and ...